For American Heart Month, learn about the advances Johnson & Johnson is making to help turn heart failure into heart recovery for the millions of adults in the U.S. living with the condition, which occurs when the heart muscle isn’t able to pump blood as well as it should.
What once seemed like an out-of-reach goal may soon be within our grasp. Take an in-depth look at how Johnson & Johnson is working toward its vision of helping create a world without cancer.
More from Johnson & Johnson
The key to slowing cognitive decline is diagnosing the disease as early as possible. And that’s exactly what Johnson & Johnson scientists are relentlessly pursuing.
The company makes the list for the 22nd year in a row, thanks to its dedication to innovation, social responsibility and more.
Scientists aren’t sure what’s behind the upward trend. That’s why Johnson & Johnson Innovation put out the call to address this troubling health disparity.
Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
Harnessing the human genome is the future of healthcare—and Johnson & Johnson is helping lead the way
The company’s partnership with the largest human genome sequencing project in the world will increase scientists’ understanding of genetic diseases and help create new interventions. Here, a look at the breakthroughs that have guided the understanding of the power of DNA.
Johnson & Johnson Announces Expansion of IMBRUVICA® (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications
IMBRUVICA® is now the only Bruton’s tyrosine kinase inhibitor (BTKi) approved with an oral suspension formulation, providing additional flexibility for patients who may have difficulty swallowing tablets or capsules
Janssen Receives Positive CHMP Opinion for CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma
Results from the Phase 3 CARTITUDE-4 study, which supported the CHMP recommendation, showed that cilta-cel has the potential to offer significant benefit to patients in earlier lines of treatment1 Most patients with multiple myeloma relapse after current standard treatments and remain in need of additional therapeutic options at earlier stages of the disease1
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Biweekly dosing with TECVAYLI®, the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility
Orthopaedic Experts Identify Best Practices for Wound Closure and Dressing Management in Total Knee and Total Hip Arthroplasty
Studies Published in The Journal of Arthroplasty Feature Consensus from 20 Orthopaedic Surgeons on Surgical Wound Management with the Goal to Reduce Variability and Promote Standardization